Wir haben ausgewählte Abstracts von unseren Partnern für Sie zusammengestellt.
AbbVie AG
- 2146 | Efficacy of Upadacitinib in Patients With Psoriatic Arthritis and Prior Exposure to Anti-TNF Therapy in the SELECT-PsA 2 Trial Through 2 Years
- 1611 | Putative Role of the Histidine and Tryptophan Biochemical Pathways in the Mode of Action of Upadacitinib in Ankylosing Spondylitis Patients: Global Metabolomic Analysis of the SELECT-AXIS 1 Study
- 0292 | Malignancy in the Upadacitinib Clinical Trial Programs for Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Amgen Switzerland AG
- 2140 | Exposure-Adjusted Incidence Rate for Adverse Events of Special Interest in Patients With Psoriatic Arthritis Treated With Apremilast
- 1187 | Obesity Burden and Effects of Apremilast on Changes in Cardiometabolic Parameters by Obesity Status in Patients with Psoriasis (PsO) or Psoriatic Arthritis (PsA) in a Real-World Setting
- 1188 | Diabetes Burden and Effects of Apremilast on Changes in Cardiometabolic Parameters in Patients with Psoriasis (PsO) or Psoriatic Arthritis (PsA) in a Real-World Setting
Biogen Switzerland AG
- 0917 | Fifty-two-week Results from a Phase 3, Randomized, Double-blind, Active-controlled Clinical Trial to Compare BAT1806/BIIB800, a Proposed Tocilizumab Biosimilar, with a Tocilizumab Reference Product in Subjects with Moderate to Severe RA with an Inadequate Response to Methotrexate
- 1433 | A 48-week Analysis of a Pan-EU Real-world Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis
Eli Lilly (Suisse) SA
- 2138 | Real-world Persistence and Treatment Patterns in Psoriatic Arthritis Patients Treated with Anti-IL17 Therapy
- 1419 | Time to Discontinuation and Effectiveness with Baricitinib in Rheumatoid Arthritis: 12-Month European Data from a Multinational, Prospective, Observational Study
- 1042 | Long-term Safety of Ixekizumab in Adult Patients with Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis
Janssen-Cilag AG
- 2115 | Early Skin and Early Enthesitis Responses in Psoriatic Arthritis Patients Treated with Guselkumab Associate with Long-term Response: Post Hoc Analysis Through 2 Years of a Phase 3 Study
- 1035 | Efficacy of Guselkumab in Three Cohorts of Biologic-Naïve PsA Patients with Axial Involvement Defined Based on Imaging and Machine-Learning Criteria: Pooled Analysis of Two Phase 3 Studies
- 2139 | Sustained Response to Guselkumab Regardless of Baseline Demographic, Disease, and Medication Characteristics in Patients with Active Psoriatic Arthritis and an Inadequate Response to TNF Inhibitors: Results from a Phase 3b Trial
MSD Merck Sharp & Dohme AG
- 0129 | Effectiveness of Golimumab in the Treatment of Patients with Active Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis Who Failed Initial TNFα Therapy: A Pooled Analysis of European Prospective Observational Studies (the GO BEYOND Program)
- 0545 | Continuing (Full or Reduced Treatment) versus Withdrawing from Golimumab Treatment in Patients with Non-radiographic Spondylarthritis Who Achieved Inactive Disease: Efficacy and Safety Results from a Placebo-Controlled, Randomized Withdrawal and Retreatment Study (GO-BACK)
Novartis Pharma Schweiz AG
- L15 | Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: A Randomized Phase IIIb Study
- 2209 | Efficacy of Secukinumab in Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis Subtypes of Juvenile Idiopathic Arthritis: Results from a Randomized, Phase 3 Study
- 0138 | Patients with Familial Mediterranean Fever (FMF) Under Canakinumab Treatment – Long-term Efficacy and Safety Interim Data of the RELIANCE Registry
Pfizer AG
Roche Pharma (Schweiz) AG
UCB-Pharma AG
- 0378 | Prevalence of Axial Spondyloarthritis (axSpA) in Patients Treated for Chronic Back Pain in Chiropractic Clinics
- 0408 | Long-Term Clinical Outcomes of Certolizumab Pegol Treatment in Patients with Active Non‑Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status
- 1010 | Comparison of Established and New, Preliminarily Proposed ASAS Cut-Offs for Inflammatory MRI Lesions in the Sacroiliac Joints of Axial Spondyloarthritis Patients and Implications for Recruitment in Clinical Studies